LncRNA ZEB1-AS1 predicts unfavorable prognosis in gastric cancer
LncRNA ZEB1 Antisense 1 (ZEB1-AS1) has been suggested to be an oncogenic role in human hepatocellular carcinoma, osteosarcoma, glioma and esophageal carcinoma progression. However, the clinical significance and biological function of ZEB1-AS1 in gastric cancer is poorly understood. Levels of ZEB1-AS...
Gespeichert in:
| Veröffentlicht in: | Surgical oncology 2017-12, Vol.26 (4), p.527-534 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 534 |
|---|---|
| container_issue | 4 |
| container_start_page | 527 |
| container_title | Surgical oncology |
| container_volume | 26 |
| creator | Li, Yanliang Wen, Xiaowen Wang, Longgang Sun, Xianjun Ma, Heng Fu, Zheng Li, Leping |
| description | LncRNA ZEB1 Antisense 1 (ZEB1-AS1) has been suggested to be an oncogenic role in human hepatocellular carcinoma, osteosarcoma, glioma and esophageal carcinoma progression. However, the clinical significance and biological function of ZEB1-AS1 in gastric cancer is poorly understood.
Levels of ZEB1-AS1 expression in gastric cancer tissues and cell lines were detected by qRT-PCR. Loss-of-function and gain-of-function studies were conducted to explore the biological function of ZEB1-AS1 in gastric cancer cells migration, invasion and EMT process. Rescued-function studies were performed to explore the association between ZEB1-AS1 and ZEB1 in gastric cancer cells migration, invasion and EMT process.
ZEB1-AS1 was overexpressed in gastric cancer tissues and cell lines, and correlated with malignant status and prognosis in gastric cancer patients. ZEB1-AS1 regulated gastric cancer cells migration, invasion and EMT process. ZEB1-AS1 positively regulated ZEB1 expression in gastric cancer cells, and had a strongly positive correlation with ZEB1 expression in gastric cancer tissues. Rescued-function studies showed ZEB1 was critical for ZEB1-AS1 induced gastric cancer cells migration, invasion and EMT process.
ZEB1-AS1 served as oncogenic roles in the regulation of gastric cancer cells migration, invasion and EMT process through modulating ZEB1.
•ZEB1-AS1 is high-expressed in gastric cancer tissues and cell lines.•ZEB1-AS1 high-expression is associated with malignant status and prognosis in gastric cancer patients.•ZEB1-AS1 served as oncogenic roles in the regulation of cells migration, invasion and EMT process through modulating ZEB1. |
| doi_str_mv | 10.1016/j.suronc.2017.09.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1961849881</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960740417302840</els_id><sourcerecordid>1961849881</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-23057701fd479bec6aada1735e1cbff439dc5e6c6a4f430c4809c3ac4aedb6f53</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi1ERZfCP0AoEhcuSWdix44viG3VQqUVSHxcuFjOZFJ5tZsUO6nEv8erbTlw6Gk0o2dmXj1CvEGoEFCfb6u0xGmkqgY0FdgKoH0mVtgaW0pZw3OxAquhNArUqXiZ0hYAtKnxhTitLaLURq3Ex81I376si19XF1iuv2NxF7kPNKdiGQd_P0Xf7TgPp9txSiEVYSxufZpjoIL8SBxfiZPB7xK_fqhn4uf11Y_Lz-Xm66eby_WmJNXouawlNMYADr0ytmPS3vcejWwYqRsGJW1PDes8V7kBUi1Ykp6U577TQyPPxPvj3Zzl98JpdvuQiHc7P_K0JIdWY6ts22JG3_2HbqcljjndgWqUMsrKTKkjRXFKKfLg7mLY-_jHIbiDYbd1R8PuYNiBddlwXnv7cHzp9tz_W3pUmoEPR4CzjfvA0SUKnFX1ITLNrp_C0x_-AuFJjSQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1965447493</pqid></control><display><type>article</type><title>LncRNA ZEB1-AS1 predicts unfavorable prognosis in gastric cancer</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Li, Yanliang ; Wen, Xiaowen ; Wang, Longgang ; Sun, Xianjun ; Ma, Heng ; Fu, Zheng ; Li, Leping</creator><creatorcontrib>Li, Yanliang ; Wen, Xiaowen ; Wang, Longgang ; Sun, Xianjun ; Ma, Heng ; Fu, Zheng ; Li, Leping</creatorcontrib><description>LncRNA ZEB1 Antisense 1 (ZEB1-AS1) has been suggested to be an oncogenic role in human hepatocellular carcinoma, osteosarcoma, glioma and esophageal carcinoma progression. However, the clinical significance and biological function of ZEB1-AS1 in gastric cancer is poorly understood.
Levels of ZEB1-AS1 expression in gastric cancer tissues and cell lines were detected by qRT-PCR. Loss-of-function and gain-of-function studies were conducted to explore the biological function of ZEB1-AS1 in gastric cancer cells migration, invasion and EMT process. Rescued-function studies were performed to explore the association between ZEB1-AS1 and ZEB1 in gastric cancer cells migration, invasion and EMT process.
ZEB1-AS1 was overexpressed in gastric cancer tissues and cell lines, and correlated with malignant status and prognosis in gastric cancer patients. ZEB1-AS1 regulated gastric cancer cells migration, invasion and EMT process. ZEB1-AS1 positively regulated ZEB1 expression in gastric cancer cells, and had a strongly positive correlation with ZEB1 expression in gastric cancer tissues. Rescued-function studies showed ZEB1 was critical for ZEB1-AS1 induced gastric cancer cells migration, invasion and EMT process.
ZEB1-AS1 served as oncogenic roles in the regulation of gastric cancer cells migration, invasion and EMT process through modulating ZEB1.
•ZEB1-AS1 is high-expressed in gastric cancer tissues and cell lines.•ZEB1-AS1 high-expression is associated with malignant status and prognosis in gastric cancer patients.•ZEB1-AS1 served as oncogenic roles in the regulation of cells migration, invasion and EMT process through modulating ZEB1.</description><identifier>ISSN: 0960-7404</identifier><identifier>EISSN: 1879-3320</identifier><identifier>DOI: 10.1016/j.suronc.2017.09.008</identifier><identifier>PMID: 29113674</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adenocarcinoma - genetics ; Adenocarcinoma - secondary ; Adenocarcinoma - therapy ; Antisense RNA ; Biocompatibility ; Biomarkers, Tumor - genetics ; Biomedical materials ; Biotechnology ; Bone cancer ; Brain tumors ; Cancer ; Cancer therapies ; Case-Control Studies ; Cell cycle ; Cell migration ; Cell Movement ; Disease Progression ; EMT ; Esophageal carcinoma ; Esophagus ; Female ; Follow-Up Studies ; Gastric cancer ; Glioma ; Hepatocellular carcinoma ; Humans ; LncRNA ; Lymphatic Metastasis ; Male ; Medical prognosis ; Medical research ; Metastasis ; Middle Aged ; Neoplasm Invasiveness ; Osteosarcoma ; Prognosis ; Proteins ; RNA, Long Noncoding - genetics ; Stomach Neoplasms - genetics ; Stomach Neoplasms - pathology ; Stomach Neoplasms - therapy ; Survival Rate ; Tissues ; Tumor cell lines ; Tumor Cells, Cultured ; ZEB1 ; ZEB1-AS1</subject><ispartof>Surgical oncology, 2017-12, Vol.26 (4), p.527-534</ispartof><rights>2017 Elsevier Ltd</rights><rights>Copyright © 2017 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-23057701fd479bec6aada1735e1cbff439dc5e6c6a4f430c4809c3ac4aedb6f53</citedby><cites>FETCH-LOGICAL-c456t-23057701fd479bec6aada1735e1cbff439dc5e6c6a4f430c4809c3ac4aedb6f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.suronc.2017.09.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29113674$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Yanliang</creatorcontrib><creatorcontrib>Wen, Xiaowen</creatorcontrib><creatorcontrib>Wang, Longgang</creatorcontrib><creatorcontrib>Sun, Xianjun</creatorcontrib><creatorcontrib>Ma, Heng</creatorcontrib><creatorcontrib>Fu, Zheng</creatorcontrib><creatorcontrib>Li, Leping</creatorcontrib><title>LncRNA ZEB1-AS1 predicts unfavorable prognosis in gastric cancer</title><title>Surgical oncology</title><addtitle>Surg Oncol</addtitle><description>LncRNA ZEB1 Antisense 1 (ZEB1-AS1) has been suggested to be an oncogenic role in human hepatocellular carcinoma, osteosarcoma, glioma and esophageal carcinoma progression. However, the clinical significance and biological function of ZEB1-AS1 in gastric cancer is poorly understood.
Levels of ZEB1-AS1 expression in gastric cancer tissues and cell lines were detected by qRT-PCR. Loss-of-function and gain-of-function studies were conducted to explore the biological function of ZEB1-AS1 in gastric cancer cells migration, invasion and EMT process. Rescued-function studies were performed to explore the association between ZEB1-AS1 and ZEB1 in gastric cancer cells migration, invasion and EMT process.
ZEB1-AS1 was overexpressed in gastric cancer tissues and cell lines, and correlated with malignant status and prognosis in gastric cancer patients. ZEB1-AS1 regulated gastric cancer cells migration, invasion and EMT process. ZEB1-AS1 positively regulated ZEB1 expression in gastric cancer cells, and had a strongly positive correlation with ZEB1 expression in gastric cancer tissues. Rescued-function studies showed ZEB1 was critical for ZEB1-AS1 induced gastric cancer cells migration, invasion and EMT process.
ZEB1-AS1 served as oncogenic roles in the regulation of gastric cancer cells migration, invasion and EMT process through modulating ZEB1.
•ZEB1-AS1 is high-expressed in gastric cancer tissues and cell lines.•ZEB1-AS1 high-expression is associated with malignant status and prognosis in gastric cancer patients.•ZEB1-AS1 served as oncogenic roles in the regulation of cells migration, invasion and EMT process through modulating ZEB1.</description><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma - secondary</subject><subject>Adenocarcinoma - therapy</subject><subject>Antisense RNA</subject><subject>Biocompatibility</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomedical materials</subject><subject>Biotechnology</subject><subject>Bone cancer</subject><subject>Brain tumors</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Case-Control Studies</subject><subject>Cell cycle</subject><subject>Cell migration</subject><subject>Cell Movement</subject><subject>Disease Progression</subject><subject>EMT</subject><subject>Esophageal carcinoma</subject><subject>Esophagus</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastric cancer</subject><subject>Glioma</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>LncRNA</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Osteosarcoma</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>RNA, Long Noncoding - genetics</subject><subject>Stomach Neoplasms - genetics</subject><subject>Stomach Neoplasms - pathology</subject><subject>Stomach Neoplasms - therapy</subject><subject>Survival Rate</subject><subject>Tissues</subject><subject>Tumor cell lines</subject><subject>Tumor Cells, Cultured</subject><subject>ZEB1</subject><subject>ZEB1-AS1</subject><issn>0960-7404</issn><issn>1879-3320</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQhi1ERZfCP0AoEhcuSWdix44viG3VQqUVSHxcuFjOZFJ5tZsUO6nEv8erbTlw6Gk0o2dmXj1CvEGoEFCfb6u0xGmkqgY0FdgKoH0mVtgaW0pZw3OxAquhNArUqXiZ0hYAtKnxhTitLaLURq3Ex81I376si19XF1iuv2NxF7kPNKdiGQd_P0Xf7TgPp9txSiEVYSxufZpjoIL8SBxfiZPB7xK_fqhn4uf11Y_Lz-Xm66eby_WmJNXouawlNMYADr0ytmPS3vcejWwYqRsGJW1PDes8V7kBUi1Ykp6U577TQyPPxPvj3Zzl98JpdvuQiHc7P_K0JIdWY6ts22JG3_2HbqcljjndgWqUMsrKTKkjRXFKKfLg7mLY-_jHIbiDYbd1R8PuYNiBddlwXnv7cHzp9tz_W3pUmoEPR4CzjfvA0SUKnFX1ITLNrp_C0x_-AuFJjSQ</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Li, Yanliang</creator><creator>Wen, Xiaowen</creator><creator>Wang, Longgang</creator><creator>Sun, Xianjun</creator><creator>Ma, Heng</creator><creator>Fu, Zheng</creator><creator>Li, Leping</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20171201</creationdate><title>LncRNA ZEB1-AS1 predicts unfavorable prognosis in gastric cancer</title><author>Li, Yanliang ; Wen, Xiaowen ; Wang, Longgang ; Sun, Xianjun ; Ma, Heng ; Fu, Zheng ; Li, Leping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-23057701fd479bec6aada1735e1cbff439dc5e6c6a4f430c4809c3ac4aedb6f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma - secondary</topic><topic>Adenocarcinoma - therapy</topic><topic>Antisense RNA</topic><topic>Biocompatibility</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomedical materials</topic><topic>Biotechnology</topic><topic>Bone cancer</topic><topic>Brain tumors</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Case-Control Studies</topic><topic>Cell cycle</topic><topic>Cell migration</topic><topic>Cell Movement</topic><topic>Disease Progression</topic><topic>EMT</topic><topic>Esophageal carcinoma</topic><topic>Esophagus</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastric cancer</topic><topic>Glioma</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>LncRNA</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Osteosarcoma</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>RNA, Long Noncoding - genetics</topic><topic>Stomach Neoplasms - genetics</topic><topic>Stomach Neoplasms - pathology</topic><topic>Stomach Neoplasms - therapy</topic><topic>Survival Rate</topic><topic>Tissues</topic><topic>Tumor cell lines</topic><topic>Tumor Cells, Cultured</topic><topic>ZEB1</topic><topic>ZEB1-AS1</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Yanliang</creatorcontrib><creatorcontrib>Wen, Xiaowen</creatorcontrib><creatorcontrib>Wang, Longgang</creatorcontrib><creatorcontrib>Sun, Xianjun</creatorcontrib><creatorcontrib>Ma, Heng</creatorcontrib><creatorcontrib>Fu, Zheng</creatorcontrib><creatorcontrib>Li, Leping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Yanliang</au><au>Wen, Xiaowen</au><au>Wang, Longgang</au><au>Sun, Xianjun</au><au>Ma, Heng</au><au>Fu, Zheng</au><au>Li, Leping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LncRNA ZEB1-AS1 predicts unfavorable prognosis in gastric cancer</atitle><jtitle>Surgical oncology</jtitle><addtitle>Surg Oncol</addtitle><date>2017-12-01</date><risdate>2017</risdate><volume>26</volume><issue>4</issue><spage>527</spage><epage>534</epage><pages>527-534</pages><issn>0960-7404</issn><eissn>1879-3320</eissn><abstract>LncRNA ZEB1 Antisense 1 (ZEB1-AS1) has been suggested to be an oncogenic role in human hepatocellular carcinoma, osteosarcoma, glioma and esophageal carcinoma progression. However, the clinical significance and biological function of ZEB1-AS1 in gastric cancer is poorly understood.
Levels of ZEB1-AS1 expression in gastric cancer tissues and cell lines were detected by qRT-PCR. Loss-of-function and gain-of-function studies were conducted to explore the biological function of ZEB1-AS1 in gastric cancer cells migration, invasion and EMT process. Rescued-function studies were performed to explore the association between ZEB1-AS1 and ZEB1 in gastric cancer cells migration, invasion and EMT process.
ZEB1-AS1 was overexpressed in gastric cancer tissues and cell lines, and correlated with malignant status and prognosis in gastric cancer patients. ZEB1-AS1 regulated gastric cancer cells migration, invasion and EMT process. ZEB1-AS1 positively regulated ZEB1 expression in gastric cancer cells, and had a strongly positive correlation with ZEB1 expression in gastric cancer tissues. Rescued-function studies showed ZEB1 was critical for ZEB1-AS1 induced gastric cancer cells migration, invasion and EMT process.
ZEB1-AS1 served as oncogenic roles in the regulation of gastric cancer cells migration, invasion and EMT process through modulating ZEB1.
•ZEB1-AS1 is high-expressed in gastric cancer tissues and cell lines.•ZEB1-AS1 high-expression is associated with malignant status and prognosis in gastric cancer patients.•ZEB1-AS1 served as oncogenic roles in the regulation of cells migration, invasion and EMT process through modulating ZEB1.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>29113674</pmid><doi>10.1016/j.suronc.2017.09.008</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0960-7404 |
| ispartof | Surgical oncology, 2017-12, Vol.26 (4), p.527-534 |
| issn | 0960-7404 1879-3320 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1961849881 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adenocarcinoma - genetics Adenocarcinoma - secondary Adenocarcinoma - therapy Antisense RNA Biocompatibility Biomarkers, Tumor - genetics Biomedical materials Biotechnology Bone cancer Brain tumors Cancer Cancer therapies Case-Control Studies Cell cycle Cell migration Cell Movement Disease Progression EMT Esophageal carcinoma Esophagus Female Follow-Up Studies Gastric cancer Glioma Hepatocellular carcinoma Humans LncRNA Lymphatic Metastasis Male Medical prognosis Medical research Metastasis Middle Aged Neoplasm Invasiveness Osteosarcoma Prognosis Proteins RNA, Long Noncoding - genetics Stomach Neoplasms - genetics Stomach Neoplasms - pathology Stomach Neoplasms - therapy Survival Rate Tissues Tumor cell lines Tumor Cells, Cultured ZEB1 ZEB1-AS1 |
| title | LncRNA ZEB1-AS1 predicts unfavorable prognosis in gastric cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A00%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LncRNA%20ZEB1-AS1%20predicts%20unfavorable%20prognosis%20in%20gastric%20cancer&rft.jtitle=Surgical%20oncology&rft.au=Li,%20Yanliang&rft.date=2017-12-01&rft.volume=26&rft.issue=4&rft.spage=527&rft.epage=534&rft.pages=527-534&rft.issn=0960-7404&rft.eissn=1879-3320&rft_id=info:doi/10.1016/j.suronc.2017.09.008&rft_dat=%3Cproquest_cross%3E1961849881%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1965447493&rft_id=info:pmid/29113674&rft_els_id=S0960740417302840&rfr_iscdi=true |